文献速递细菌感染、耐药与抗菌药物

延长脉冲式非达霉素与传统剂量在高复发风险艰难梭菌感染患者中的比较:多中心队列研究

Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of Clostridioides difficile infection: a multicentre cohort study.
PubMed 文献 · Clin Microbiol Infect · 2026-07-11

这项西班牙19中心回顾性队列研究纳入991例艰难梭菌感染(CDI)患者,比较延长脉冲式非达霉素剂量(FEPD)与传统非达霉素剂量(FCD)治疗后12周内复发率。粗复发率FCD组12.7%、FEPD组12.8%(OR 1.01,95%CI 0.67-1.54,p 0.95);倾向评分匹配(每组263例)后OR 1.04(95%CI 0.62-1.74,p 0.895),IPTW调整后OR 0.90(95%CI 0.59-1.39,p 0.644),均无显著差异。结论提示两种方案在真实世界中预防CDI复发效果相似。

要点

  • FEPD与FCD治疗后12周复发率无显著差异(匹配后OR 1.04,95%CI 0.62-1.74)。
  • 复发中位时间为治疗结束后25天(IQR 15-44),两组相似。
  • 敏感性分析和亚组分析结果一致,但需随机对照试验确认。

核心结论

  • 在多中心真实世界队列中,FEPD与FCD预防CDI复发的效果相似。
  • 两组治疗结束后至复发的中位时间相似。

研究设计与样本

  • 回顾性多中心队列研究,覆盖西班牙19个中心。
  • 纳入2021年1月至2023年4月期间接受任一剂量非达霉素治疗的CDI病例。
  • 共评估1465例发作,最终分析991例:FCD组726例(73.3%),FEPD组265例(26.7%)。
  • 采用倾向评分匹配分析,并辅以IPTW、排除bezlotoxumab治疗患者、 immortal time偏倚调整和竞争风险分析等敏感性分析。

主要发现

  • 粗复发率FCD组12.7%、FEPD组12.8%(OR 1.01;95%CI 0.67-1.54;p 0.95)。
  • 倾向评分匹配分析(每组263例)无显著差异(OR 1.04;95%CI 0.62-1.74;p 0.895)。
  • IPTW调整后OR 0.90(95%CI 0.59-1.39;p 0.644)。
  • 复发中位时间为治疗结束后25天(IQR 15-44),组间相似。

临床怎么用

  • 在真实临床实践中,FEPD与FCD预防CDI复发的效果相当,可根据临床情况选择剂量方案。

局限性

  • 为回顾性队列研究,需随机对照试验确认 findings。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Fidaxomicin has consistently shown lower recurrence rates than vancomycin for Clostridioides difficile infection (CDI), with the fidaxomicin extended-pulsed dosage (FEPD) achieving rates as low as 6% in a comparative trial, suggesting potential superiority over conventional fidaxomicin dosing (FCD). A subsequent single-centre retrospective study reported no significant difference between FEPD and FCD, possibly due to limited sample size. This study aims to compare CDI recurrence rates within 12 weeks after treatment completion between patients treated with FEPD and those receiving FCD in a large multicentre cohort. METHODS: A retrospective multicentre cohort study was conducted across 19 Spanish centres, including all CDI cases treated with fidaxomicin at either dosage between January 2021 and April 2023. To assess recurrence, a propensity score (PS)-matching analysis was performed, adjusting for potential confounders and prognostic factors for recurrence. Sensitivity analyses included inverse probability of treatment weighting (IPTW), exclusion of bezlotoxumab-treated patients, adjustment for immortal time bias, and competing-risks analysis. RESULTS: Of 1465 episodes evaluated, 991 were analysed: 726 (73.3%) received FCD and 265 (26.7%) FEPD. Crude recurrence rates in the FCD and FEPD regimens were 12.7% and 12.8%, respectively (OR: 1.01; 95% CI: 0.67-1.54; p 0.95). In the PS-matched analysis (263 per group), no significant difference was observed (OR: 1.04; 95% CI: 0.62-1.74; p 0.895), nor after IPTW adjustment (OR: 0.90; 95% CI: 0.59-1.39; p 0.644). Additional sensitivity and subgroup analyses yielded consistent results. Median time to recurrence from the end of treatment was 25 days (interquartile range: 15-44), similar among groups. CONCLUSIONS: This large multicentre cohort study suggests similar effectiveness of both fidaxomicin regimens for preventing CDI recurrence in real-world clinical practice. Time to recurrence from the end of treatment was similar in both groups. Randomised controlled trials are needed to confirm these findings.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Rubio-Martín E, Escudero-Sánchez R, López-Contreras J, et al. Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of Clostridioides difficile infection: a multicentre cohort study. Clin Microbiol Infect. 2026. PMID: 42435853. doi:10.1016/j.cmi.2026.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。